

Brand Name: Voydeya

Generic: danicopan


Type: small molecule

Year Accepted/Phase: 2024

Mechanism:

Danicopan is a selective inhibitor of the C5a receptor, which plays a role in the activation of the complement system. By blocking this receptor, danicopan may reduce inflammation and tissue damage associated with complement-mediated diseases.

Chemical Structure:



Indication:

Voydoya is being investigated for the treatment of PNH, C3 glomerulopathy, and potentially other complement-mediated diseases.

Clinical trials:

Clinical Trials for Various Diseases

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/34314483/>

Purpose: Evaluate the efficacy and safety of danicopan (Voydoya) in patients with PNH, C3 glomerulopathy, and other complement-mediated diseases.

Dates: Clinical trials for Voydoya have been ongoing in the 2010s and 2020s.

Results: Specific trial results may vary depending on the disease being studied, but the overall aim is to demonstrate the ability of danicopan to inhibit the C5a receptor and modulate complement activity to improve clinical outcomes.

Impact: Positive results from these trials could lead to the approval of Voydoya for the treatment of PNH, C3 glomerulopathy, and other complement-mediated diseases.